Get the Stockscreener App
13.35
0.68%
0.09
After Hours:
13.27
-0.08
-0.60%
Organon Co stock is traded at $13.35, with a volume of 7.24M.
It is up +0.68% in the last 24 hours and up +109.91% over the past month.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
See More
Previous Close:
$13.26
Open:
$13.29
24h Volume:
7.24M
Relative Volume:
0.83
Market Cap:
$3.51B
Revenue:
$6.16B
Net Income/Loss:
$246.00M
P/E Ratio:
14.30
EPS:
0.9333
Net Cash Flow:
$508.00M
1W Performance:
+0.23%
1M Performance:
+109.91%
6M Performance:
+109.25%
1Y Performance:
+53.10%
1-Day Range:
$13.27
$13.35
1-Week Range:
$13.25
$13.39
52-Week Range:
$5.69
$13.39
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.35 | 3.48B | 6.16B | 246.00M | 508.00M | 0.9333 |
LLY
Lilly Eli Co
|
988.87 | 863.14B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.55 | 539.70B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.11 | 368.19B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
181.24 | 284.52B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.15 | 279.37B | 65.59B | 8.93B | 12.36B | 3.5532 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Halper Sadeh LLC is Investigating Whether MKC, LEG, OGN, KW are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Sun Pharma to acquire Organon in $11.75 billion all-cash deal - MSN
Shanghvi’s audacious bet with $11.75-billion Sun-Organon deal - Fortune India
Sun Pharma Organon Deal: Indian Pharma King Ne Kar Liya $11.75B Ka Acquisition! Par Debt Ka Risk Kitna? - Whalesbook
A $12 billion US deal pushes Sun Pharma into big leagues - Moneycontrol.com
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? - marketscreener.com
Organon & Co. Reports Q1 2026 Financial Results: Revenue, Net Income, and Key Disclosures from Latest 10-Q Filing - Minichart
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Why Organon will need Dilip Shanghvi’s masterstroke - The Economic Times
Organon & Co. 1Q 2026: Revenue $1.46B, EPS $0.55— 10-Q Summary - TradingView
Sun Pharma to acquire Organon (NYSE: OGN) for $14 per share in cash - Stock Titan
Organon & Co is the best performing healthcare stock in April (XLV:NYSEARCA) - Seeking Alpha
Key deals this week: Organon, ARC Resources, Nebius, Eli Lilly and more - MSN
India's biggest pharma deal: Sun Pharma to acquire US-based Organon in $11.75 billion deal - Business Standard
Organon stock surges 31% on sweetened $13 billion takeover offer from Sun Pharma - MSN
Sun Pharma's $11.75B Organon Buy: Speciality Drugs, Global Expansion & More - Deccan Herald
Sun Pharma to acquire Organon for $11.75bn - MSN
India’s Sun Pharma plots $12 billion Organon buyout for global reach - MSN
Sun Pharma exploring Eurobonds, bond swaps to fund US-based Organon buy - Business Standard
Sun Pharma to buy Organon in $11.75B deal, expanding global reach - MSN
Mitsubishi UFJ Trust & Banking Corp Sells 202,370 Shares of Organon & Co. $OGN - MarketBeat
Sun Pharma shares jump 9% as $11.75‑billion Organon buy seals entry into biosimilars, deal expected to close in 2027 - MSN
Sun Pharma shares jump 7% as India's largest drugmaker to buy US firm Organon in $11.75 billion deal - MSN
Organon Buyout And POHERDY Approval Shape Returns And Valuation Outlook - simplywall.st
MSN Money - MSN
Organon jumps 15% as Sun Pharma agrees $11.8bn buyout - MSN
The Sun Pharma-Organon deal, UAE’s divorce from OPEC, and more… - Finshots
Sun Pharma is marrying Organon - Finshots
Organon & Co. (NYSE:OGN) Short Interest Update - MarketBeat
Organon (OGN)’s Investors React Strongly as Sun Pharma Bets Big on Specialty Drug Expansion - Insider Monkey
OGN News Today | Why did Organon & Co. stock go up today? $OGN - MarketBeat
Sun Pharma to acquire Organon for Inorganic Growth - The Financial World
Organon & Co To Go Ex-Dividend On May 11th, 2026 With 0.02 USD Dividend Per Share - Moomoo
Organon (OGN) Margin Hit To 3% Tests Bullish Earnings Recovery Story - simplywall.st
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates - StockStory
Organon & Co. (NYSE:OGN) Declares $0.02 Quarterly Dividend - MarketBeat
Sun Pharma To Acquire Former Merck Spinoff, Organon for $11.75 Bn - DCAT Value Chain Insights
Jim Cramer Says “Organon’s Done” Upon a Caller’s Inquiry - Insider Monkey
Vanguard Capital Management reports 13.7M shares in Organon (OGN) - Stock Titan
Organon Reports Results for the First Quarter Ended March 31, 2026 - BioSpace
Sun Pharma’s $11.75 billion Organon deal: not all brokers are hailing the high ROCE swap for leverage - Moneycontrol.com
Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Organon (OGN) Q1 Earnings and Revenues Miss Estimates - Yahoo Finance
India's Sun Pharma to buy US-listed Organon in about $11.8 billion deal - MSN
Earnings Flash (OGN) Organon & Co. Reports Q1 Revenue $1.46B, vs. FactSet Est of $1.49B - marketscreener.com
Earnings Flash (OGN) Organon & Co. Posts Q1 Adjusted EPS $0.71 per Share, vs. FactSet Est of $0.83 - marketscreener.com
Organon misses estimates as revenue declines 9% By Investing.com - Investing.com Canada
Organon (NYSE: OGN) Q1 2026 revenue dips as adjusted EPS falls - Stock Titan
Organon: Q1 Earnings Snapshot - marketscreener.com
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):